4.5 Article

Structural insights into binding of therapeutic channel blockers in NMDA receptors

Journal

NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 29, Issue 6, Pages 507-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41594-022-00772-0

Keywords

-

Funding

  1. NIH [NS111745, MH085926, F32MH121061, S10OD028632-01]
  2. Robertson funds at CSHL
  3. Doug Fox Alzheimer's fund
  4. Austin's purpose
  5. Heartfelt Wing Alzheimer's fund
  6. Gertrude and Louis Feil Family Trust
  7. BBSRC [BB/M006395/1]

Ask authors/readers for more resources

Excitatory signaling mediated by N-methyl-d-aspartate receptor (NMDAR) is critical for brain development and function, as well as for neurological diseases and disorders. Channel blockers of NMDARs are of medical interest owing to their potential for treating depression, Alzheimer's disease, and epilepsy. However, precise mechanisms underlying binding and channel blockade have remained limited owing to challenges in obtaining high-resolution structures at the binding site within the transmembrane domains.
Excitatory signaling mediated by N-methyl-d-aspartate receptor (NMDAR) is critical for brain development and function, as well as for neurological diseases and disorders. Channel blockers of NMDARs are of medical interest owing to their potential for treating depression, Alzheimer's disease, and epilepsy. However, precise mechanisms underlying binding and channel blockade have remained limited owing to challenges in obtaining high-resolution structures at the binding site within the transmembrane domains. Here, we monitor the binding of three clinically important channel blockers: phencyclidine, ketamine, and memantine in GluN1-2B NMDARs at local resolutions of 2.5-3.5 angstrom around the binding site using single-particle electron cryo-microscopy, molecular dynamics simulations, and electrophysiology. The channel blockers form different extents of interactions with the pore-lining residues, which control mostly off-speeds but not on-speeds. Our comparative analyses of the three unique NMDAR channel blockers provide a blueprint for developing therapeutic compounds with minimal side effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available